Hector E Tamez, Alejandra L Tamez, Lucas A Garza, Mayra I Hernandez, Ana C Polanco. J Diabetes Metab Disord 2015
Times Cited: 23
Times Cited: 23
Times Cited
Times Co-cited
Similarity
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
Robert R Henry, Payal Thakkar, Cindy Tong, David Polidori, Maria Alba. Diabetes Care 2015
Robert R Henry, Payal Thakkar, Cindy Tong, David Polidori, Maria Alba. Diabetes Care 2015
78
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
69
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
65
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
60
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
60
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
52
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
52
Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
30
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
30
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
30
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
30
Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Ingrid M Libman, Kellee M Miller, Linda A DiMeglio, Kathleen E Bethin, Michelle L Katz, Avni Shah, Jill H Simmons, Michael J Haller, Sripriya Raman, William V Tamborlane,[...]. JAMA 2015
Ingrid M Libman, Kellee M Miller, Linda A DiMeglio, Kathleen E Bethin, Michelle L Katz, Avni Shah, Jill H Simmons, Michael J Haller, Sripriya Raman, William V Tamborlane,[...]. JAMA 2015
26
SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
26
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux, Po Sing Leung. PLoS One 2016
Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux, Po Sing Leung. PLoS One 2016
26
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.
Helena W Rodbard, Anne L Peters, April Slee, Anjun Cao, Shana B Traina, Maria Alba. Diabetes Care 2017
Helena W Rodbard, Anne L Peters, April Slee, Anjun Cao, Shana B Traina, Maria Alba. Diabetes Care 2017
26
The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
26
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.
Julio Rosenstock, Ele Ferrannini. Diabetes Care 2015
Julio Rosenstock, Ele Ferrannini. Diabetes Care 2015
21
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
21
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.
Bruce A Perkins, David Z I Cherney, Nima Soleymanlou, Justin A Lee, Helen Partridge, Holly Tschirhart, Bernard Zinman, Roger Mazze, Nora Fagan, Stefan Kaspers,[...]. PLoS One 2015
Bruce A Perkins, David Z I Cherney, Nima Soleymanlou, Justin A Lee, Helen Partridge, Holly Tschirhart, Bernard Zinman, Roger Mazze, Nora Fagan, Stefan Kaspers,[...]. PLoS One 2015
21
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
21
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
Robert R Henry, Paresh Dandona, Jeremy Pettus, Sunder Mudaliar, John Xu, Lars Hansen. Diabetes Obes Metab 2017
Robert R Henry, Paresh Dandona, Jeremy Pettus, Sunder Mudaliar, John Xu, Lars Hansen. Diabetes Obes Metab 2017
21
Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
Nitesh D Kuhadiya, Husam Ghanim, Aditya Mehta, Manisha Garg, Salman Khan, Jeanne Hejna, Barrett Torre, Antoine Makdissi, Ajay Chaudhuri, Manav Batra,[...]. J Clin Endocrinol Metab 2016
Nitesh D Kuhadiya, Husam Ghanim, Aditya Mehta, Manisha Garg, Salman Khan, Jeanne Hejna, Barrett Torre, Antoine Makdissi, Ajay Chaudhuri, Manav Batra,[...]. J Clin Endocrinol Metab 2016
21
SGLT inhibition and euglycaemic diabetic ketoacidosis.
Julia Hine, Heather Paterson, Esha Abrol, David Russell-Jones, Roselle Herring. Lancet Diabetes Endocrinol 2015
Julia Hine, Heather Paterson, Esha Abrol, David Russell-Jones, Roselle Herring. Lancet Diabetes Endocrinol 2015
17
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
17
GLYCEMIC EFFECTS OF SGLT-2 INHIBITOR CANAGLIFLOZIN IN TYPE 1 DIABETES PATIENTS USING THE DEXCOM G4 PLATINUM CGM.
Nicholas B Argento, Katherine Nakamura. Endocr Pract 2016
Nicholas B Argento, Katherine Nakamura. Endocr Pract 2016
28
Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
17
Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
W Tang, T A Leil, E Johnsson, D W Boulton, F LaCreta. Diabetes Obes Metab 2016
W Tang, T A Leil, E Johnsson, D W Boulton, F LaCreta. Diabetes Obes Metab 2016
26
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
Elizabeth M Lamos, Lisa M Younk, Stephen N Davis. Expert Opin Investig Drugs 2014
Elizabeth M Lamos, Lisa M Younk, Stephen N Davis. Expert Opin Investig Drugs 2014
17
Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
17
THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES.
Bruce W Bode, Satish K Garg. Endocr Pract 2016
Bruce W Bode, Satish K Garg. Endocr Pract 2016
17
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
17
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
17
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
17
Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
Xu-Ping Yang, Dan Lai, Xiao-Yan Zhong, Hong-Ping Shen, Yi-Lan Huang. Eur J Clin Pharmacol 2014
Xu-Ping Yang, Dan Lai, Xiao-Yan Zhong, Hong-Ping Shen, Yi-Lan Huang. Eur J Clin Pharmacol 2014
13
Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus.
Aris Liakos, Thomas Karagiannis, Eleni Bekiari, Panagiota Boura, Apostolos Tsapas. Ther Adv Endocrinol Metab 2015
Aris Liakos, Thomas Karagiannis, Eleni Bekiari, Panagiota Boura, Apostolos Tsapas. Ther Adv Endocrinol Metab 2015
14
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
Nelson B Watts, John P Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger. J Clin Endocrinol Metab 2016
Nelson B Watts, John P Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger. J Clin Endocrinol Metab 2016
13
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
Yehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, Sam Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Ele Ferrannini, Vivian A Fonseca, Alan J Garber, George Grunberger,[...]. Endocr Pract 2016
Yehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, Sam Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Ele Ferrannini, Vivian A Fonseca, Alan J Garber, George Grunberger,[...]. Endocr Pract 2016
13
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
13
The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova,[...]. PLoS One 2014
Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova,[...]. PLoS One 2014
13
Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
Nitesh D Kuhadiya, Ritu Malik, Natalie J Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi, Paresh Dandona. Endocr Pract 2013
Nitesh D Kuhadiya, Ritu Malik, Natalie J Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi, Paresh Dandona. Endocr Pract 2013
13
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
13
Potential role of non-insulin adjunct therapy in Type 1 diabetes.
P George, R J McCrimmon. Diabet Med 2013
P George, R J McCrimmon. Diabet Med 2013
13
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
J P H Wilding, V Woo, K Rohwedder, J Sugg, S Parikh. Diabetes Obes Metab 2014
J P H Wilding, V Woo, K Rohwedder, J Sugg, S Parikh. Diabetes Obes Metab 2014
13
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
13
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
13
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Qun Li, Hiroshi Tomiyama,[...]. J Pharm Pharmacol 2014
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Qun Li, Hiroshi Tomiyama,[...]. J Pharm Pharmacol 2014
13
Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice.
Takashi Hatanaka, Daisuke Ogawa, Hiromi Tachibana, Jun Eguchi, Tatsuyuki Inoue, Hiroshi Yamada, Kohji Takei, Hirofumi Makino, Jun Wada. Pharmacol Res Perspect 2016
Takashi Hatanaka, Daisuke Ogawa, Hiromi Tachibana, Jun Eguchi, Tatsuyuki Inoue, Hiroshi Yamada, Kohji Takei, Hirofumi Makino, Jun Wada. Pharmacol Res Perspect 2016
13
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
13
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.
Michael J Jurczak, Hui-Young Lee, Andreas L Birkenfeld, Francois R Jornayvaz, David W Frederick, Rebecca L Pongratz, Xiaoxian Zhao, Gilbert W Moeckel, Varman T Samuel, Jean M Whaley,[...]. Diabetes 2011
Michael J Jurczak, Hui-Young Lee, Andreas L Birkenfeld, Francois R Jornayvaz, David W Frederick, Rebecca L Pongratz, Xiaoxian Zhao, Gilbert W Moeckel, Varman T Samuel, Jean M Whaley,[...]. Diabetes 2011
13
13
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.